Abstract：
OBJECTIVE: We assessed the utility of red blood cell (RBC) CD105 and side scatter (SSC) parameters by flow cytometry for the detection of low-grade myelodysplastic neoplasms (MDS) in bone marrow specimens.
METHODS: Ten RBC parameters incorporating CD105 or SSC combined with the Meyerson-Alayed scoring system (MASS) metrics were retrospectively evaluated by flow cytometry for utility in detecting low-grade MDS (n = 56) compared with cytopenic controls (n = 86).
RESULTS: Myelodysplastic neoplasms were associated with 7 of the RBC parameters in univariate analysis. Multivariate analysis using cutoff values based on optimal and 95% specificity levels of the RBC metrics and the MASS parameters revealed the SSC ratio of CD105-positive and CD105-negative RBC fractions (CD105+/- SSC); the percentage and coefficient of variation of the CD105-positive fraction of RBCs (CD105%, CD105+CV) emerged as significant RBC variables. Two simple scoring schemes using these RBC values along with MASS parameters were identified: 1 using CD105+/- SSC, CD105%, and CD105+CV combined with the percentage of CD177-positive granulocytes (CD177%), myeloblast percentage (CD34%), and granulocyte SSC (GranSSC), and the other incorporating CD105+/- SSC, CD105+CV, CD177%, CD34%, GranSSC, and B-cell progenitor percentage. Both demonstrated a sensitivity of approximately 80%, with a specificity of roughly 90% for the detection of MDS compared with cytopenic controls.
CONCLUSIONS: The red blood cell parameter, CD105+/- SSC, appears to be beneficial in the evaluation of low-grade MDS by flow cytometry.
METHODS: Ten RBC parameters incorporating CD105 or SSC combined with the Meyerson-Alayed scoring system (MASS) metrics were retrospectively evaluated by flow cytometry for utility in detecting low-grade MDS (n = 56) compared with cytopenic controls (n = 86).
RESULTS: Myelodysplastic neoplasms were associated with 7 of the RBC parameters in univariate analysis. Multivariate analysis using cutoff values based on optimal and 95% specificity levels of the RBC metrics and the MASS parameters revealed the SSC ratio of CD105-positive and CD105-negative RBC fractions (CD105+/- SSC); the percentage and coefficient of variation of the CD105-positive fraction of RBCs (CD105%, CD105+CV) emerged as significant RBC variables. Two simple scoring schemes using these RBC values along with MASS parameters were identified: 1 using CD105+/- SSC, CD105%, and CD105+CV combined with the percentage of CD177-positive granulocytes (CD177%), myeloblast percentage (CD34%), and granulocyte SSC (GranSSC), and the other incorporating CD105+/- SSC, CD105+CV, CD177%, CD34%, GranSSC, and B-cell progenitor percentage. Both demonstrated a sensitivity of approximately 80%, with a specificity of roughly 90% for the detection of MDS compared with cytopenic controls.
CONCLUSIONS: The red blood cell parameter, CD105+/- SSC, appears to be beneficial in the evaluation of low-grade MDS by flow cytometry.
摘要：
目的：我们通过流式细胞术评估了红细胞（RBC）CD105和侧向散射（SSC）参数在检测骨髓标本中低级别骨髓增生异常肿瘤（MDS）中的实用性。
方法：通过流式细胞术回顾性评估结合CD105或SSC与Meyerson-Alayed评分系统（MASS）指标的10个RBC参数在检测低度MDS（n=56）中的实用性。
结果：单因素分析中骨髓增生异常肿瘤与7个红细胞参数相关。使用基于RBC指标和MASS参数的最佳和95％特异性水平的截止值进行多变量分析，揭示了CD105阳性和CD105阴性RBC分数的SSC比率（CD105/-SSC）；RBC的CD105阳性分数的百分比和变异系数（CD105%，CD105+CV)作为显著的RBC变量出现。确定了使用这些RBC值以及MASS参数的两个简单评分方案：1使用CD105+/-SSC，CD105%,和CD105+CV与CD177阳性粒细胞的百分比（CD177%），成髓细胞百分比（CD34%），和粒细胞SSC（GranSSC），另一个结合了CD105+/-SSC，CD105+CV,CD177%,CD34%,GranSSC,和B细胞祖细胞百分比。两者都表现出大约80%的灵敏度，与细胞减少性对照相比，MDS检测的特异性约为90%。
结论：红细胞参数，CD105+/-SSC,通过流式细胞术评估低度MDS似乎是有益的。
方法：通过流式细胞术回顾性评估结合CD105或SSC与Meyerson-Alayed评分系统（MASS）指标的10个RBC参数在检测低度MDS（n=56）中的实用性。
结果：单因素分析中骨髓增生异常肿瘤与7个红细胞参数相关。使用基于RBC指标和MASS参数的最佳和95％特异性水平的截止值进行多变量分析，揭示了CD105阳性和CD105阴性RBC分数的SSC比率（CD105/-SSC）；RBC的CD105阳性分数的百分比和变异系数（CD105%，CD105+CV)作为显著的RBC变量出现。确定了使用这些RBC值以及MASS参数的两个简单评分方案：1使用CD105+/-SSC，CD105%,和CD105+CV与CD177阳性粒细胞的百分比（CD177%），成髓细胞百分比（CD34%），和粒细胞SSC（GranSSC），另一个结合了CD105+/-SSC，CD105+CV,CD177%,CD34%,GranSSC,和B细胞祖细胞百分比。两者都表现出大约80%的灵敏度，与细胞减少性对照相比，MDS检测的特异性约为90%。
结论：红细胞参数，CD105+/-SSC,通过流式细胞术评估低度MDS似乎是有益的。
